PMID- 26607297
OWN - NLM
STAT- MEDLINE
DCOM- 20161007
LR  - 20161230
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 15
IP  - 2
DP  - 2016
TI  - Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.
PG  - 249-64
LID - 10.1517/14740338.2016.1125467 [doi]
AB  - INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) inhibitors such as alogliptin are 
      becoming more widely established as treatment options for patients with type 2 
      diabetes (T2DM) because of their ability to improve glycemic control without 
      increasing the risk of hypoglycemia or weight gain. New therapies with improved 
      safety profiles are needed, especially because of the chronic and progressive 
      nature of T2DM. AREAS COVERED: In this article, the overall safety and 
      tolerability of alogliptin are evaluated based upon a review of the literature. 
      In particular, adverse events (AEs) that have been of interest for the DPP-4 
      class of drugs, such as the risk of major cardiovascular (CV) events and acute 
      pancreatitis, will be investigated in detail. EXPERT OPINION: Alogliptin is 
      generally well-tolerated in a broad range of patient populations including 
      different ethnic groups and the elderly. In the pivotal EXAMINE clinical trial, 
      alogliptin was found not to be associated with an increased risk of major CV 
      events or acute pancreatitis/pancreatic cancer.
FAU - Yabe, Daisuke
AU  - Yabe D
AD  - a Yutaka Seino Distinguished Center for Diabetes Research , Kansai Electric Power 
      Medical Research Institute , Kobe , Japan.
AD  - b Center for Diabetes, Endocrinology and Metabolism , Kansai Electric Power 
      Hospital , Osaka , Japan.
AD  - c Center for Clinical Nutrition and Metabolism , Kansai Electric Power Hospital , 
      Osaka , Japan.
FAU - Seino, Yutaka
AU  - Seino Y
AD  - a Yutaka Seino Distinguished Center for Diabetes Research , Kansai Electric Power 
      Medical Research Institute , Kobe , Japan.
AD  - b Center for Diabetes, Endocrinology and Metabolism , Kansai Electric Power 
      Hospital , Osaka , Japan.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Piperidines)
RN  - 56HH86ZVCT (Uracil)
RN  - JHC049LO86 (alogliptin)
SB  - IM
MH  - Aged
MH  - Animals
MH  - Diabetes Mellitus, Type 2/drug therapy/physiopathology
MH  - Dipeptidyl-Peptidase IV Inhibitors/*adverse effects/therapeutic use
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/*adverse effects/therapeutic use
MH  - Piperidines/*adverse effects/therapeutic use
MH  - Uracil/adverse effects/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - Alogliptin
OT  - dipeptidyl peptidase-4 inhibitors
OT  - safety
OT  - tolerability
OT  - type 2 diabetes
EDAT- 2015/11/27 06:00
MHDA- 2016/10/08 06:00
CRDT- 2015/11/27 06:00
PHST- 2015/11/27 06:00 [entrez]
PHST- 2015/11/27 06:00 [pubmed]
PHST- 2016/10/08 06:00 [medline]
AID - 10.1517/14740338.2016.1125467 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2016;15(2):249-64. doi: 10.1517/14740338.2016.1125467.